We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...
Whether you have type 2 diabetes, obesity or just a few extra pounds that you’d like some help shedding, chances are you’re ...
Good Housekeeping UK on MSN17h
Everything you need to know about weightloss drugsWhat about the side-effects? Will I regain all my weight? Dr Sarah Jarvis has the answers to your burning questions.
A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...
GlobalData on MSN18h
AbbVie enters obesity space with $2.3bn Gubra dealAbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire rights to a long-acting amylin ...
AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based ...
The FDA has declared that the shortage of popular weight-loss drugs, including Ozempic and Wegovy, is officially over.
You've probably heard about the relatively new weight loss medications and the results some people have seen with them and you may have wondered if they could help you.
If obesity is seen not just as a personal struggle but a disease of public health concern, we can look for systemic solutions ...
Australian telehealth startup Eucalyptus has made $200 million in 18 months as demand for weight loss drugs soars. Here's how ...
Stifel downgraded Novo Nordisk (NVO) to Hold from Buy with a price target of DKK 700, down from DKK 780. Novo is “no longer the same stock that ...
IPC Indice de Precios Y Cotizaciones 52,325.73-281.88-0.54% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback